Five Next-Gen Psychedelics Clinical Trials Taking
Post# of 135
(Total Views: 199)
Posted On: 06/02/2022 4:41:57 PM
Five Next-Gen Psychedelics Clinical Trials Taking Place in 2022
Numerous studies have shown that psychedelics may be useful in the treatment of mental health conditions, including depression and post-traumatic stress disorder. Companies such as MindMed, Cybin Inc. and Field Trip Health have been conducting clinical trials to test the safety and effectiveness of these medicines in comparison to currently used drugs. Below are some of the next-generation psychedelics that will be in trials this year.
Cybin’s CYB003 candidate
Cybin’s next-generation psilocybin candidate will enter a phase 1/2a trial this year, after the company receives regulatory approval.
The focus of the trial will be the candidate’s effectiveness in treating major depressive disorder. However, researchers will also look into the drug’s variability of effect between people. Variability occurs when the drug administered metabolizes differently in different individuals, causing a variety of effect intensities.
Cybin has released a statement noting that preclinical evidence has shown that its formulation counteracts these effects. Additionally, the company stated that CYB003’s onset action is faster than the original and its effects are less variable than conventional medicines.
MindMed’s MM-110 compound
MindMed developed this candidate to help treat opioid use disorder. MM-110, or 18-MC as it is popularly known, has already completed phase 1 trials, which demonstrated that the compound was well tolerated in individuals and caused no adverse events.
MM-110 is a synthetic molecule based on ibogaine. Various studies have shown that ibogaine may be useful in the treatment of addiction despite its side effects. Its downsides include lengthy hallucination and cardiovascular effects that may in some cases lead to cardiac arrest and even death.
The compound, which the company claims has no side effects, is set to enter phase 2a effectiveness trials this quarter.
Field Trip Health’s FT-104 candidate
This candidate is a first-generation psychedelic that will be undergoing a phase 1 clinical trial before this year ends. Field Trip’s focus is testing the compound’s effectiveness in treating post-partum depression and treatment-resistant depression.
Small Pharma’s SPL028 candidate
This next-generation DMT compound will begin its phase I safety trial during the second half of this year. DMT has a short duration that may not be enough for it to be clinically effective. The company will focus on finding a duration that allows the SPL028 to be effective as well as look into whether intramuscular delivery or intravenous delivery is the most effective.
Clearmind Medicine’s MEAI molecule
The company plans to enter its MEAI molecule into phase I trials before this year’s end. Its trial focus will be on the molecule’s effectiveness in treating alcohol use disorder. If proven effective, the molecule could revolutionize how we treat alcohol addiction.
As all these clinical trials and product development progress, entities such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) could have an upper hand since they are already delivering novel ketamine treatments legally, and any formulation approved would just add to their existing line-up, which already has traction on the market.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Numerous studies have shown that psychedelics may be useful in the treatment of mental health conditions, including depression and post-traumatic stress disorder. Companies such as MindMed, Cybin Inc. and Field Trip Health have been conducting clinical trials to test the safety and effectiveness of these medicines in comparison to currently used drugs. Below are some of the next-generation psychedelics that will be in trials this year.
Cybin’s CYB003 candidate
Cybin’s next-generation psilocybin candidate will enter a phase 1/2a trial this year, after the company receives regulatory approval.
The focus of the trial will be the candidate’s effectiveness in treating major depressive disorder. However, researchers will also look into the drug’s variability of effect between people. Variability occurs when the drug administered metabolizes differently in different individuals, causing a variety of effect intensities.
Cybin has released a statement noting that preclinical evidence has shown that its formulation counteracts these effects. Additionally, the company stated that CYB003’s onset action is faster than the original and its effects are less variable than conventional medicines.
MindMed’s MM-110 compound
MindMed developed this candidate to help treat opioid use disorder. MM-110, or 18-MC as it is popularly known, has already completed phase 1 trials, which demonstrated that the compound was well tolerated in individuals and caused no adverse events.
MM-110 is a synthetic molecule based on ibogaine. Various studies have shown that ibogaine may be useful in the treatment of addiction despite its side effects. Its downsides include lengthy hallucination and cardiovascular effects that may in some cases lead to cardiac arrest and even death.
The compound, which the company claims has no side effects, is set to enter phase 2a effectiveness trials this quarter.
Field Trip Health’s FT-104 candidate
This candidate is a first-generation psychedelic that will be undergoing a phase 1 clinical trial before this year ends. Field Trip’s focus is testing the compound’s effectiveness in treating post-partum depression and treatment-resistant depression.
Small Pharma’s SPL028 candidate
This next-generation DMT compound will begin its phase I safety trial during the second half of this year. DMT has a short duration that may not be enough for it to be clinically effective. The company will focus on finding a duration that allows the SPL028 to be effective as well as look into whether intramuscular delivery or intravenous delivery is the most effective.
Clearmind Medicine’s MEAI molecule
The company plans to enter its MEAI molecule into phase I trials before this year’s end. Its trial focus will be on the molecule’s effectiveness in treating alcohol use disorder. If proven effective, the molecule could revolutionize how we treat alcohol addiction.
As all these clinical trials and product development progress, entities such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) could have an upper hand since they are already delivering novel ketamine treatments legally, and any formulation approved would just add to their existing line-up, which already has traction on the market.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)